{"related:ZDkBYYb9O2cJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","url":"https://www.nature.com/articles/nature13904?page=11","authors":["T Powles","T Powles JP Eder","T Powles JP Eder GD Fine","T Powles JP Eder GD Fine FS Braiteh","T Powles JP Eder GD Fine FS Braiteh Y Loriot…"],"year":2014,"numCitations":1829,"pdf":"http://sys.91sqs.net/mobilenews/pdfs/%E6%8A%97PD-L1%E6%8A%97%E4%BD%93MPDL3280A%E5%85%B7%E6%9C%89%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%E8%BD%AC%E7%A7%BB%E6%80%A7%E8%86%80%E8%83%B1%E7%99%8C%E7%9A%84%E7%96%97%E6%95%88.pdf","citationUrl":"http://scholar.google.com/scholar?cites=7438817963127421284&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZDkBYYb9O2cJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7438817963127421284&hl=en&as_sdt=0,5","publication":"nature.com","p":1,"exp":1596879364853},{"title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","url":"https://www.nature.com/articles/nature14011?page=1","authors":["RS Herbst","RS Herbst JC Soria","RS Herbst JC Soria M Kowanetz","RS Herbst JC Soria M Kowanetz GD Fine","RS Herbst JC Soria M Kowanetz GD Fine O Hamid…"],"year":2014,"numCitations":3082,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4836193/","citationUrl":"http://scholar.google.com/scholar?cites=16172811975131816039&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Z2Dq3M1eceAJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16172811975131816039&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a …","url":"https://www.sciencedirect.com/science/article/pii/S0140673616005614","authors":["JE Rosenberg","JE Rosenberg J Hoffman"],"year":2016,"numCitations":2031,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242/","citationUrl":"http://scholar.google.com/scholar?cites=5432023266656526845&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:_SG4hGFsYksJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5432023266656526845&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Safety, activity, and immune correlates of anti–PD-1 antibody in cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","authors":["SL Topalian","SL Topalian FS Hodi","SL Topalian FS Hodi JR Brahmer…"],"year":2012,"numCitations":9290,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","citationUrl":"http://scholar.google.com/scholar?cites=10859371970938450815&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:f7Oeq0U9tJYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10859371970938450815&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","url":"https://www.nature.com/articles/nature13954?page=4","authors":["PC Tumeh","PC Tumeh CL Harview","PC Tumeh CL Harview JH Yearley","PC Tumeh CL Harview JH Yearley IP Shintaku…"],"year":2014,"numCitations":3357,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418/","citationUrl":"http://scholar.google.com/scholar?cites=8600773541923439091&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:88Hsr_cVXHcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8600773541923439091&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1411087","authors":["SM Ansell","SM Ansell AM Lesokhin","SM Ansell AM Lesokhin I Borrello…"],"year":2015,"numCitations":2576,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1411087","citationUrl":"http://scholar.google.com/scholar?cites=9724708986138050565&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:BcDOlkwb9YYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9724708986138050565&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Safety and activity of anti–PD-L1 antibody in patients with advanced cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","authors":["JR Brahmer","JR Brahmer SS Tykodi","JR Brahmer SS Tykodi LQM Chow…"],"year":2012,"numCitations":5915,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","citationUrl":"http://scholar.google.com/scholar?cites=13360512895833832804&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZH0zFbETarkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13360512895833832804&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","authors":["O Hamid","O Hamid C Robert","O Hamid C Robert A Daud","O Hamid C Robert A Daud FS Hodi…"],"year":2013,"numCitations":3154,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","citationUrl":"http://scholar.google.com/scholar?cites=164069860268346458&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WoykK6vkRgIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=164069860268346458&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Improved survival with ipilimumab in patients with metastatic melanoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1003466","authors":["FS Hodi","FS Hodi SJ O'Day","FS Hodi SJ O'Day DF McDermott…"],"year":2010,"numCitations":12023,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1003466","citationUrl":"http://scholar.google.com/scholar?cites=2675556821352765108&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:tNYa2cB8ISUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2675556821352765108&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569690/","authors":["C Massard","C Massard MS Gordon","C Massard MS Gordon S Sharma","C Massard MS Gordon S Sharma S Rafii…"],"year":2016,"numCitations":530,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569690/","citationUrl":"http://scholar.google.com/scholar?cites=13099960749517958788&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:hO6TJuVozLUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13099960749517958788&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"}]}